Non-small cell lung cancer
Conditions
Interventions
All patients undergo FLT-PET/MRI before and 2 and 6 weeks after initiation of PD-1 immune checkpoint inhibitors.
Sponsors
Third department of internal medicine, Universtiy of Fukui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically confirmed advanced non-small cell lung cancer (NSCLC) 2) Indication of PD-1 immune checkpoint inhibitors (Nivolumab or Pembrolizumab) 3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 4) Patient with evaluable lesion based on RECIST 5) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Pregnant woman 2) Patients with metalic device in their body 3) Patients with claustrophobia 4) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 5) Patients with collagen vascular disease or autoimmune diseases 6) Other cases attending physician it is determined unsuitable for registration of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between serial FLT-PET/MRI findings of the tumor and progression free survival and tumor response. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Association of serial change of FLT-PET/MRI findings with overall survival. 2. Association of FLT-PET/MRI findings and PD-L1 expression of lung cancer. | — |
Countries
Japan
Contacts
Public ContactYukihiro Umeda
University of Fukui Third department of internal medicine
Outcome results
None listed